Creation of an Additional Glycosylation Site as a Mechanism for Type I Antithrombin Deficiency

Summary

We report the identification of a new mutation resulting in type I antithrombin (AT) deficiency and the mechanism by which the deficiency arose. The single base substitution of G to A at nucleotide 2709 was identified in a proband with a family history of venous thrombosis. The mutation results in a substitution of 82 Ser by Asn, creating a new glycosylation site. Expression studies were then carried out, to confirm Asn-linked glycosylation occurred at this consensus site and that this resulted in the AT deficient phenotype. Cell-free translations using rabbit reticulocyte lysate in the presence of microsomes demonstrated that the 82 Asn variant was post-translationally processed efficiently. The 82 Asn variant protein was of a higher molecular weight than normal AT, consistent with the addition of a fifth glycan chain. Incubation of translation product with endoglycosidase H, confirmed that the higher molecular weight product had resulted from additional carbohydrate. Expression of the 82 Asn variant in COS-7 cells resulted in intracellular accumulation, with a low level of secretion of the protein into culture supernatant, consistent with type I AT deficiency. The addition of an extra carbohydrate side chain to residue 82 of antithrombin may block post-translational folding, trapping the variant intracellulary.

Keywords

Antithrombin - glycosylation - venous thrombosis

• References

• 1 Rodgers GM, Chandler WL. Laboratory and clinical aspects of inherited thrombotic disorders. Am J Hematol 1992; 41: 113-22.
• 2 Franzen LE, Svensson S, Larm O. Structural studies on the carbohydrate portion of human antithrombin III. J Biol Chem 1980; 255: 5090-3.
• 3 Peterson CB, Blackburn MN. Antithrombin conformation and the catalytic role of heparin. II. Is the heparin-induced conformational change in anti-thrombin required for rapid inactivation of thrombin?. J Biol Chem 1987; 262: 7559-66.
• 4 Brennan SO, George PM, Jordan RE. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135. FEBS Lett 1987; 219: 431-6.
• 5 Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry 1993; 32: 4216-24.
• 6 Brennan SO, Borg JY, George PM, Soria C, Soria J, Caen J, Carrell RW. New carbohydrate site in mutant antithrombin (7 Ile–Asn) with decreased heparin affinity. FEBS Lett 1988; 237: 118-22.
• 7 Bayston TA, Tripodi A, Mannucci PM, Thompson E, Ireland H, Fitsches AC, Hananeia L, Olds RJ, Lane DA. Familial overexpression of beta anti-thrombin caused by an Asn135Thr substitution. Blood 1999; 93: 4242-7.
• 8 Chowdhury V, Olds RJ, Lane DA, Conard J, Pabinger I, Ryan K, Bauer KA, Bhavnani M, Abildgaard U, Finazzi G. et al. Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haemat 1993; 84: 656-61.
• 9 Fitches AC, Appleby R, Lane DA, De Stefano V, Leone G, Olds RJ. Impaired cotranslational processing as a mechanism for type I antithrombin deficienty. Blood 1998; 92: 4671-6.
• 10 Sheffield WP, Blajchman MA. Site-directed mutagenesis of the P2 residue of human antithrombin. FEBS Letters 1994; 339: 147-50.
• 11 Emmerich J, Vidaud D, Alhenc-Gelas M, Chadeuf G, Gouault-Heilmann M, Aillaud MF, Aiach M. Three novel mutations of antithrombin inducing high-molecular-mass compuds. Arterioscler Thromb 1994; 14: 1958-65.
• 12 Lane D, Bayston T, Olds R, Fitches A, Cooper D, Millar D, Jochmans K, Perry D, Okajima K, Thein S, Emmerich J. Antithrombin mutation database: 2nd (1997) update. Thromb Haemost 1997; 77: 197-211.
• 13 Nilsson IM, von Heijne G. Determination of the distance between the oligosaccharyltransferase active site and the endoplasmic reticulum membrane. J Biol Chem 1993; 268: 5798-801.
• 14 von Heijne G. Signal sequences. The limits of variation. Journal of Molecular Biology 1985; 184: 99-105.
• 15 Reddy PS, Corley RB. Assembly, sorting, and exit of oligomeric proteins from the endoplasmic reticulum. Bioessays 1998; 20: 546-54.
• 16 Wickner S, Maurizi MR, Gottesman S. Posttranslational quality control: folding, refolding, and degrading proteins. Science 1999; 20: 546-54.
• 17 Marquardt T, Helenius A. Misfolding and aggregation of newly synthesized proteins in the endoplasmic reticulum. J Cell Biol 1992; 117: 505-13.
• 18 Liu Y, Choudhury P, Cabral CM, Sifers RN. Oligosaccaride modification in the early secretory pathway directs the selection of a misfolded gylcoprotein for degradation by the proteasome. J Biol Chem 1999; 274: 5861-7.